NCT03016819 2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3 Recruiting
Clinical Trials
20 trialsNCT07359053 2026-01-22
MAGNATE-S
Shanghai 6th People's Hospital
Phase 2 Recruiting
NCT07205185 2025-10-03
A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.
Fudan University
Phase 2 Not yet recruiting
NCT04165330 2025-02-24
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Sarcoma Oncology Research Center, LLC
Phase 1/2 Active not recruiting
NCT06699576 2024-11-21
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
Hansoh BioMedical R&D Company
Phase 1 Not yet recruiting
NCT05301764 2024-10-15
A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma
Lyvgen Biopharma Holdings Limited
Phase 1/2 Recruiting
NCT06506838 2024-08-12
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Guangdong Provincial People's Hospital
Phase 4 Recruiting
NCT05490667 2023-10-30
Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor
Henan Cancer Hospital
Phase NA Unknown
NCT03890068 2023-08-01
Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma
Sun Yat-sen University
Phase 2 Unknown
NCT04172805 2023-04-12
Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
Sun Yat-sen University
Phase 2 Unknown
NCT05612191 2022-11-28
Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)
Advenchen Laboratories, LLC
Available
NCT05602415 2022-11-02
Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma
Ruijin Hospital
Phase 2 Unknown
NCT04765228 2021-02-21
Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma
Fudan University
Phase 2 Unknown
NCT04106024 2019-09-26
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
Cttq
Phase 2 Unknown
NCT03946943 2019-07-10
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
The First Hospital of Jilin University
Phase 2 Unknown
NCT03815474 2019-07-09
ALTER-S005
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT03527888 2019-05-21
Study of Anlotinib in Patients With Primary Malignant Bone Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT03416517 2019-02-15
Anlotinib and Irinotecan for Ewing Sarcoma
Peking University People's Hospital
Phase 1/2 Unknown
NCT03792542 2019-01-03
Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT02449343 2017-04-25
Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown